Abstract library

233 results for "Rank-Preserving Structural Failure Time model".
#336 Overall Survival (OS) Analysis of Sunitinib (SU) After Adjustment for Crossover (CO) in Patients With Pancreatic Neuroendocrine Tumors (NET)
Introduction: A recent phase 3 trial of SU in pancreatic NET showed an improvement in progression-free survival (PFS) and OS. However, the OS benefit was confounded by early CO from placebo (PBO) to SU treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Jack Ishak
#538 Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Adam Johns
Authors: Johns A, Eatock M, Johal S, ...
#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Keywords: sutent, OS
#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mónica Inês
Authors: Soares M, Inês M, Contente M, ...
#2260 Carcinoid Heart Failure in a Metastatic Duodenal Neuroendocrine Tumor: A Challenging Case Report.
Introduction: Carcinoid heart disease (CHD) is a potenzial fatal cardiac manifestation, characterized by fibrous endocardial thickening involving right-sided heart valves. In 70% of cases, CHD occurs in advanced small bowel NETs with carcinoid syndrome (CS). Serotonin seems to play a main role. Early recognition and surgical intervention may improve the outcome of patients.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Dr Anna La Salvia
#2270 Development of Pre-Clinical NEN Models – Limitations and Opportunities
Introduction: Pre-clinical research in neuroendocrine neoplasia (NEN) has long been impaired by the paucity of NET and NEC cell lines. Furthermore, established models have not been widely available or displayed unusual features (eg. p53 and ras mutations, high proliferation rate).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Benten D, Unrau L, Fahl M, ...
Keywords: cell line
#613 Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models
Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Carleen Cullinane
Authors: Cullinane C, Waldeck K, Kirby L, Eu P, ...
#1382 Appropriate Indication of Organ Preserving Surgery for Pancreatic Neuroendocrine Neoplasm
Introduction: Organ preserving surgery(OPS) has been accepted for pancreatic neuroendocrine neoplasm(PNEN), particularly in a small and low malignant tumors.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Takahiro Tsuchikawa
#1945 Metabolic Adaptation to Anti-Angiogenic Therapy
Introduction: Although anti-angiogenic inhibition (AI) therapy has demonstrable efficacy in mouse models of cancer and in certain types of human cancer, responses are typically transitory, followed by resumption of malignant progression that limits survival benefit. Unconventional modes of evasive/adaptive resistance underlay the eventual failures of anti-angiogenic therapy. Functionally established resistance mechanisms include revascularization mediated by alternative pro-angiogenic signals, protection by peri-vascular macrophages and monocytes to induce an immunosuppressive microenvironment, and normal vessel cooption via heightened local invasion and distant metastasis. All three mechanisms have been documented in the prototypical RIP-Tag2 mouse model of multistep tumorigenesis, in which the angiogenic switch is a discrete step in the pathway to invasive pancreatic neuroendocrine cancer.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Elizabeth Allen
Authors: Allen E, ...
Keywords: AI/mTOR
#536 Orexins Exert a Pro-Apoptotic Effect on Neuroendocrine Tumors (NETs) in an Ex Vivo Culture Model of Tissue Slices
Introduction: Ex vivo culture models of tissue slices are suitable to test the effect of antitumor agents in human tumors. The orexins are neuropeptides binding to G protein-coupled receptors (OX1-R and OX2-R), exerting a pro-apoptotic effect in human colon and pancreatic cancer cell lines.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Maxime Palazzo